Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda investors back $59 billion Shire deal, but wary of debt load

12/05/2018 | 05:04am EST
FILE PHOTO: The logo of Takeda Pharmaceutical Co. is displayed at the company's news conference venue in Tokyo

OSAKA (Reuters) - Takeda Pharmaceutical shareholders approved on Wednesday its $59 billion (46.3 billion pounds) takeover of London-listed Shire, creating a global powerhouse with a stronger drugs pipeline but one that is saddled with massive debt.

Takeda will be joining the ranks of the world's top 10 drugmakers and gaining expertise in rare diseases through the deal, the biggest overseas acquisition by a Japanese company.

It will also become one of the most indebted. In addition to issuing new shares, the company has secured $30.9 billion in bank loans.

The company's high debt levels were a top concern for shareholders who gathered at an extraordinary meeting in Osaka, western Japan, although almost 90 percent of them voted to approve the deal as expected.

"I want to keep my Takeda shares into the future, but now I am worried about further declines in the share price," said Satoshi Ito, a 75-year-old shareholder. He abstained from voting.

Takeda shares have fallen around 25 percent since the drugmaker revealed its interest in the acquisition in March. They closed up 1 percent at 4,240 yen on Wednesday.

Shire shares gained 2.6 percent to 46.69 pounds on relief Takeda's board had won its nine-month battle to persuade shareholders of the merits of the tie-up.

The acquisition is expected to close on Jan. 8. It remains subject to Shire shareholder approval at meetings due later on Wednesday and sanctioning at a court hearing expected to be held on Jan. 3.

DEBTS, DESCENDANTS AND DIVESTITURES

A small group of Takeda investors, including descendants of the company's founder, had actively opposed the deal.

"We are definitely against this because the financial risks are too great and the expected benefits are quite limited," said Kazuhisa Takeda, a former director of the drugmaker and a member of the founding family, ahead of the meeting.

"I think M&A is quite necessary for Takeda's future but Shire is not the answer."

Chief Executive Christophe Weber has promised to turn the deal profitable by slashing costs. It predicts annual savings of at least $1.4 billion three years after completion, and expects to boost underlying earnings significantly from the first full year after closing.

Takeda also has a plan to sell up to $10 billion worth of non-core assets to pay back debt. Andy Plump, Takeda’s global head of R&D, told Reuters that accelerated deleveraging was needed to keep its credit rating at a safe level.

"We have a plan for divestiture that gets us to a place in three to five years that our credit agencies are OK with. Our credit rating is likely to tick down a notch, but still above junk bond status, which is critical for us," he said in an interview.

Analysts have said it may be difficult to integrate the two companies. Toshiba's acquisition of Westinghouse over a decade ago and Japan Post Holdings' $4.9 billion bet on Toll Holdings are widely seen as examples of many Japanese companies having paid high valuations in cross-border deals only to face massive write-downs later.

But they also said Takeda has little choice but to seek growth abroad, with industry pressure to gain access to cutting-edge treatments amid declining revenue from older drugs that must compete with cheaper generics.

Even with the acquisition of Shire, some said Takeda will need to bolster its lineup of experimental therapies to compete in the longer term.

Shire's haemophilia business, for example, is already starting to face strong pressure from a competing drug being marketed by Roche as well as new gene therapies now in development.

"It's crucial whether the drugmaker can reinvest profits from the deal into seeds for developing future drugs," said Kazuaki Hashiguchi, a senior drugs analyst at Daiwa Securities.

"The benefits of the deal will last for a limited time, as no treatments can avoid patent expiration."

(Reporting by Takashi Umekawa, with additional reporting by Julie Steenhuysen in Chicago and Ben Hirschler in London; Editing by Ritsuko Ando, Muralikumar Anantharaman and Mark Potter)

By Takashi Umekawa


ę Reuters 2018
Stocks mentioned in the article
ChangeLast1st jan.
AMP LIMITED 0.53% 0.945 End-of-day quote.-39.42%
JAPAN POST HOLDINGS CO., LTD. 1.23% 873.9 End-of-day quote.8.86%
JUST GROUP PLC -0.38% 79.2 Delayed Quote.13.30%
LETS HOLDINGS GROUP CO., LTD. 1.98% 6.71 End-of-day quote.-13.75%
LOOK HOLDINGS INCORPORATED 3.18% 1298 End-of-day quote.35.63%
ROCHE HOLDING AG -0.33% 362.25 Delayed Quote.17.62%
SEEK LIMITED 1.61% 34.75 End-of-day quote.21.80%
TAKEDA PHARMACEUTICAL COMPANY LIMITED 1.55% 3070 End-of-day quote.-18.24%
THE GLOBAL LTD. 4.69% 201 End-of-day quote.-22.69%
TOSHIBA CORPORATION 2.53% 4743 End-of-day quote.64.40%
US DOLLAR / JAPANESE YEN (USD/JPY) -0.03% 113.015 Delayed Quote.9.39%
WILL GROUP, INC. 0.99% 1321 End-of-day quote.31.31%
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
12/03Takeda's LIVTENCITYTM (maribavir) Now Available for Certain Individuals Ages 12 Years a..
AQ
12/03Japanese Shares Close With Gains on Japan Services Data
MT
12/02Takeda Says Livtencity Commercially Available in the US for Patients 12 Years and Older
MT
12/02Takeda's LIVTENCITY™ (maribavir) Now Available for Certain Individuals Ages 12 Ye..
BU
12/02Takeda Pharmaceutical Company Limited Announces its LIVTENCITY? Now Available for Certa..
CI
12/02Takeda Pharmaceutical Buys Back Shares for $441 Million
MT
12/01GENERAL ANNOUNCEMENT : :Takeda Provides Update on Status of Acquisition of Own Shares
PU
12/01TAKEDA PHARMACEUTICAL : Provides Update on Status of Acquisition of Own Shares
PU
11/30Takeda Announces U.S. Corporate Social Responsibility (CSR) Program Aimed to Help Reduc..
BU
11/30GENERAL ANNOUNCEMENT : :The 145th Interim Business Report (April 1, 2021 - September 30, 2..
PU
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2022 3 407 B 30 162 M 30 162 M
Net income 2022 223 B 1 970 M 1 970 M
Net Debt 2022 3 334 B 29 516 M 29 516 M
P/E ratio 2022 21,4x
Yield 2022 5,86%
Capitalization 4 782 B 42 287 M 42 326 M
EV / Sales 2022 2,38x
EV / Sales 2023 2,25x
Nbr of Employees 47 099
Free-Float 98,2%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | 4502 | JP3463000004 | MarketScreener
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 3 070,00 JPY
Average target price 4 322,86 JPY
Spread / Average Target 40,8%
EPS Revisions
Managers and Directors
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-18.24%42 287
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641